ASCO Post launches in print, online

Share this article:
The American Society of Clinical Oncology (ASCO) and Harborside Press launched the inaugural print issue of ASCO Post in June, and launched a website home for the title last month.

ASCO Post, distributed for free to ASCO members in the US, can be read online at ASCOPost.com. Qualified hematologists and oncologists in the US and abroad are also eligible for a free print subscription by request, according to Harborside Press spokesperson Conor Lynch. Circulation numbers are close to 26,000, said Lynch.

The print edition, described as a “newspaper-style” publication in the mission statement, covers oncology meetings around the world, offers summaries of clinical literature from other general and specialty journals, provides cancer-related political commentary, and details specific oncology cases. Columns from editor-in-chief James Armitage, a former ASCO president, will be featured in the title, along with columns from affiliates Richard Boxer, Nora Janjan, Allen Lichter, John Marshall and George Sledge.

For 2010, ASCO Post will be published monthly, but will increase its publishing cycle to 18 issues per year in 2011, according to Lynch. Banners will appear on the website, and traditional advertising will be present in the print issue, said Lynch. A survey of articles on the ASCO Post homepage included updated ASCO guidelines on the subject of aromatase inhibitors usage in postmenopausal women with breast cancer, new clinical results showing denosumab's superiority to zoledronic acic in delaying some skeletal events, and an article penned by ASCO CEO Allen Lichter.

Separately, the British Medical Journal (BMJ) announced that BMJ Open, a new open access online journal would be launching in autumn 2010. That journal will feature peer-reviewed research articles “dedicated exclusively to medicine,” according to the announcement.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...